251251
Antiarrítmicos
15. The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with
atrial fibrillation. N Engl J Med. 2002;347:1825‑1833
16. Beauchamp A, Worcester M, Ng A, et al. Attendance at cardiac rehabilitation is associated
with lower all cause mortality after 14 years of follow‑up. Heart. 2013; 99:620‑5
17. Mendes M. Reabilitação cardíaca em Portugal: a intervenção que falta! Saúde & Tecnologia.
2009; 3:5‑9
18. Cynthia Sanosky, Mary Bowen, Andrew Peterson. Dysrithmias. En: Virginia Poole Arcangelo,
Andrew M. Peterson Lippincott Williams & Wilkins, 2006. Pharmacotherapeutics for
Advanced Practice: A Practical Approach, Volume 536.P259‑285
19. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving
encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med.
1991; 324:781‑788.
20. Waldo A, Camm J, de Ruyter H, et al. Effect of d‑sotalol on mortality in patients with
left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;
348:7‑12
21. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial
infarction in patients with frequent or repetitive ventricular premature depolarisations:
CAMIAT. Lancet. 1197; 349:675‑682
22. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality
in patients with leftventricular dysfunction after recent myocardial infarction: EMIAT. Lancet
1997; 349:667‑674
23. Florent Boutitie, Jean‑Pierre Boissel, Stuart J. Connolly, et al. Amiodarone Interaction With
β
‑Blockers. Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial)
and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. Circulation.
1999; 99:2268‑75
24. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta‑blockers, amiodarone plus
beta‑blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators:
The OPTIC study: a randomized trial. JAMA. 2006;295:165‑171
25. Baquero GA, Banchs JE, Depalma S, et al. Dofetilide reduces the frequency of ventricular
arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophyzol.
2012;23:296‑301
26. Eric S. Williams, Mohan N. Viswanathan. Current and Emerging Antiarrhythmic Drug
Therapy for Ventricular Tachycardia. Cardiol Ther. 2013; 2: 27‑46
27. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden
and ICD shocks in patients with drug‑refractory ICD shocks. Pacing Clin Electrophysiol.
2011;34:1600‑6
